Immune reconstitution after hematopoietic cell transplantation

Current Opinion in Hematology

Volumn 19, Issue 4, 2012, Pages 324-355

  Bosch, Mark ^a   Khan, Faisal M ^a   Storek, Jan ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

hematopoietic stem cell transplantation; immune reconstitution; immune system; immunity; lymphocytes

Indexed keywords

COMPLEMENT; IMMUNOGLOBULIN A; LYSOZYME;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL TRANSPLANTATION; DENDRITIC CELL; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RECONSTITUTION; IMMUNE SYSTEM; IMMUNITY; IMMUNOPROPHYLAXIS; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NATURAL KILLER CELL TRANSPLANTATION; NEUTROPHIL; PHOTOTHERAPY; PLASMA CELL; PRIORITY JOURNAL; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT OUTCOME;

ADAPTIVE IMMUNITY; ANTIGENS; B-LYMPHOCYTES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, INNATE; T-LYMPHOCYTES;

EID: 84862146190     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328353bc7d     Document Type: Review

References (172)

1. Chaushu G, Itzkovitz-Chaushu S, Yefenof E, et al. A longitudinal follow-up of salivary secretion in bone marrow transplant patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79:164-169.
2. Khan FM, Sy S, Louie P, et al. Epithelial cells in PBSC grafts: source of donortype epithelial cells after allogeneic transplantation? Bone MarrowTransplant 2012; 47:461-462.
3. Khan FM, Sy S, Louie P, et al. Nasal epithelial cells of donor origin after allogeneic hematopoietic cell transplantation are generated at a faster rate in the first 3 months compared with later posttransplantation. Biol Blood Marrow Transplant 2010; 16:1658-1664.
4. Naughton MA, Botto M, Carter MJ, et al. Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans. J Immunol 1996; 156:3051-3056. (Pubitemid 126660656)
5. Mullighan CG, Heatley S, Doherty K, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 2002; 99:3524-3529. (Pubitemid 34534518)
6. Alper CA, Johnson AM, Birtch AG, Moore FD. Human C'3: evidence for the liver as the primary site of synthesis. Science 1969; 163:286-288.
7. Gea-Banacloche J. Granulocyte transfusions: Where is the controversy? Cytotherapy 2011; 13:389-390.
8. De Angelis C, Mancusi A, Ruggeri L, et al. Expansion of CD56-negative, CD16-positive, KIR-expressing natural killer cells after T cell-depleted haploidentical hematopoietic stem cell transplantation. Acta Haematologica 2011; 126:13-20.
9. Laport GG, Sheehan K, Baker J, et al. Adoptive immunotherapy with cytokineinduced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17:1679-1687.
10. Marcenaro E, Carlomagno S, Pesce S, et al. Bridging innate NK cell functions with adaptive immunity. Adv Exp Med Biol 2011; 780: 45-55.
11. Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18:1835-1838. (Pubitemid 39530014)
12. Curti A, Ruggeri L, D'Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011; 118: 3273-3279.
13. Beziat V, Nguyen S, Exley M, et al. Shaping of iNKT cell repertoire after unrelated cord blood transplantation. Clin Immunol 2010; 135:364-373.
14. Haraguchi K, Takahashi T, Hiruma K, et al. Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34:595-602. (Pubitemid 39341539)
15. Bosch M, Dhadda M, Hoegh-Petersen M, et al. Immune reconstitution after antithymocyte globulin (ATG)-conditioned hematopoietic cell transplantation (HCT). Blood (ASH Annual Meeting Abstracts). 2011; 118:abstr. 1981.
16. de Lalla C, Rinaldi A, Montagna D, et al. Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4-subset dynamics and correlates with remission state. J Immunol 2011; 186:4490-4499.
17. Yang J, Gao L, Liu Y, et al. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation. Transfusion 2010; 50:407-417.
18. Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002; 99:1442-1448. (Pubitemid 34547103)
19. Shlomchik WD. Antigen presentation in graft-vs-host disease. Exp Hematol 2003; 31:1187-1197. (Pubitemid 37510023)
20. Hashimoto D, Merad M. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome. Semin Immunol 2011; 23:50-57.
21. Mackall C, Fry T, Gress R, et al. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant 2009; 44:457-462.
22. Storek J, Witherspoon R. Immuological reconstitution after hematopoietic stem cell transplant. In: Atkinson K, Champlin R, Ritz J, editors. Clinical bone marrow and blood stem cell transplantation. 3rd ed. Cambridge, United Kingdom: Cambridge University Press; 2004. pp. 194-226.
23. Noel G, Bruniquel D, Birebent B, et al. Patients suffering from acute graftversus-host disease after bone-marrow transplantation have functional CD4+CD25hiFoxp3+ regulatory T cells. Clin Immunol 2008; 129:241-248.
24. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921-3928.
25. Storek J. Immunological reconstitution after hematopoietic cell transplantation-its relation to the contents of the graft. Exp Opin Biol Therapy (Informa) 2008; 8:583-597. (Pubitemid 351685024)
26. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98:579-585.
27. Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 2008; 14:807-816. (Pubitemid 351773157)
28. Joao C, Porrata LF, Inwards DJ, et al. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant 2006; 37:865-871.
29. Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006; 107:1688-1695. (Pubitemid 43242410)
30. Savani BN, Mielke S, Rezvani K, et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:1216-1223. (Pubitemid 47413017)
31. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104:2254-2262. (Pubitemid 39331820)
32. Le Blanc K, Barrett AJ, Schaffer M, et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant 2009; 15:1108-1115.
33. Burke MJ, Vogel RI, Janardan SK, et al. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant 2011; 17:831-840.
34. Montero A, Savani BN, Shenoy A, et al. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant 2006; 12:1318-1325. (Pubitemid 44858265)
35. Ciurea SO, Mulanovich V, Jiang Y, et al. Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:1169-1175.
36. Storek J, Espino G, Dawson MA, et al. Low B cell and monocyte counts on day 80 are associated with high infection rates between day 100 and 365 after allogeneic marrow transplantation. Blood 2000; 96:3290-3293.
37. Novitzky N, Davison GM, Hale G, Waldmann H. Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome. Transplantation 2002; 74:1551-1559. (Pubitemid 36014228)
38. Podgorny PJ, Liu Y, Ugarte-Torres A, et al. Immune cell subsets in haematopoietic cell transplant recipients associated with graft-versus-host disease or infections. EBMT Abstract. Bone Marrow Transplant 2011; 46 (Suppl 1): S168.
39. Heimfeld S, Gooley T, Flowers M, et al. Effect of peripheral blood stem cell (PBSC) graft composition on graft versus host disease (GVHD) and mortality after allogeneic transplantation. Blood (ASH Annual Meeting Abstracts). 2010; 116:abstr. 676.
40. Kim DH, Sohn SK, Won DI, et al. Rapid helper T-cell recovery above 200 x 106/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37:1119-1128. (Pubitemid 43871522)
41. Berger M, Figari O, Bruno B, et al. Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. Bone Marrow Transplant 2008; 41:55-62.
42. McIver ZA, Melenhorst JJ, Grim A, et al. Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplantations: T cell subset frequencies predict outcome. Biol Blood Marrow Transplant 2011; 17:1846-1854.
43. Merindol N, Champagne MA, Duval M, Soudeyns H. CD8+ T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse. Blood 2011; 118:4480-4488.
44. Hoegh-Petersen M, Goodyear D, Geddes MN, et al. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transplant 2011; 46:1104-1102.
45. Gratama JW, Boeckh M, Nakamura R, et al. Immune monitoring with iTAg MHC tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 2010; 116:1655-1662.
46. Krause H, Hebart H, Jahn G, et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19:1111-1116. (Pubitemid 27267735)
47. Parkman R, Cohen G, Carter SL, et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006; 12:919-927.
48. Brown JA, Stevenson K, Kim HT, et al. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood 2010; 115:4111-4119.
49. Chang YJ, Zhao XY, Huang XJ. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplat 2008; 14:323-334.
50. Gallez-Hawkins GM, Franck AE, Li X, et al. Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection. Biol Blood Marrow Transplant 2011; 17:1662-1672.
51. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116:2411-2419.
52. Tomblyn M, Young JA, Haagenson MD, et al. Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biol Blood Marrow Transplant 2010; 16:1155-1161.
53. Rajasekar R, Mathews V, Lakshmi KM, et al. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD. Biol Blood Marrow Transplant 2008; 14:344-350. (Pubitemid 351218203)
54. Watanabe N, Narita M, Furukawa T, et al. Kinetics of pDCs, mDCs, gammadeltaT cells and regulatory T cells in association with graft versus host disease after hematopoietic stem cell transplantation. Int J Lab Hematol 2011; 33:378-390.
55. Perez-Martinez A, Iyengar R, Gan K, et al. Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17:598-607.
56. Rajasekar R, Lakshmi KM, George B, et al. Dendritic cell count in the graft predicts relapse in patients with hematologic malignancies undergoing an HLA-matched related allogeneic peripheral blood stem cell transplant. Biol Blood Marrow Transplant 2010; 16:854-860.
57. Chien JW, Zhang XC, Fan W, et al. Evaluation of published single nucleotide polymorphisms associated with acute graft versus host disease. Blood 2012. [Epub ahead of print].
58. Clark WB, Brown-Gentry KD, Crawford DC, et al. Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. Blood 2011; 118:1140-1144.
59. Rocha V, Franco RF, Porcher R, et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100:3908-3918. (Pubitemid 35396855)
60. Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient-and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116:5394-5402.
61. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766-1777.
62. Chien JW, Boeckh MJ, Hansen JA, Clark JG. Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Blood 2008; 111:2462-2469. (Pubitemid 351451461)
63. Mullighan CG, Heatley SL, Danner S, et al. Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood 2008; 112:2120-2128.
64. Hansen JA, Chien JW, Warren EH, et al. Defining genetic risk for graft-versushost disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr Opin Hematol 2010; 17:483-492.
65. Dickinson AM. Risk assessment in haematopoietic stem cell transplantation: pretransplant patient and donor factors: non-HLA genetics. Best Prac Res Clin Haematol 2007; 20:189-207. (Pubitemid 46613453)
66. Martin-Antonio B, Granell M, Urbano-Ispizua A. Genomic polymorphisms of the innate immune system and allogeneic stem cell transplantation. Expert Rev Hematol 2010; 3:411-427.
67. Loeffler J, Ok M, Morton OC, et al. Genetic polymorphisms in the cytokine and chemokine system: their possible importance in allogeneic stem cell transplantation. Curr Top Microbiol Immunol 2010; 341:83-96.
68. Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatricextensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008; 111:3276-3285.
69. Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113:3865-3874.
70. Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leukemia Lymphoma 2010; 51:376-389.
71. Lied GA, Berstad A. Functional and clinical aspects of the B cell activating factor (BAFF): a narrative review. Scand J Immunol 2011; 73:1-7.
72. Geddes M, Storek J. Immune reconstitution following hematopoietic stemcell transplantation. Best Prac Res Clin Haematol 2007; 20:329-348. (Pubitemid 46585969)
73. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010; 115:3861-3868.
74. Krenger W, Blazar BR, Hollander GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood 2011; 117:6768-6776.
75. Auletta JJ, Lazarus HM. Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant 2005; 35:835-857. (Pubitemid 40667627)
76. Kobbe G, Bruns I, Schroeder T, et al. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010; 21:1898-1904.
77. Elad S, Luboshitz-Shon N, Cohen T, et al. A randomized controlled trial of visible-light therapy for the prevention of oral mucositis. Oral Oncol 2011; 47:125-130.
78. Silva GB, Mendonca EF, Bariani C, et al. The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed Laser Surg 2011; 29:27-31.
79. Atkinson K, Bradstock K, Biggs JC, et al. GM-CSF after allogeneic BMT: accelerated recovery of neutrophils, monocytes and lymphocytes. Aust NZ J Med 1991; 21:686-692.
80. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800. (Pubitemid 26327536)
81. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97:3380-3389.
82. Hashimoto D, Chow A,Greter M, et al. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med 2011; 208:1069-1082.
83. Hokland M, Jacobsen N, Ellegaard J, Hokland P. Natural killer function following allogeneic bone marow transplantation. Transplantation 1988; 45: 1080-1084.
84. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2100. (Pubitemid 34229476)
85. Olson JA, Leveson-Gower DB, Gill S, et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 2010; 115:4293-4301.
86. Bornhauser M, Thiede C, Brendel C, et al. Stable engraftment after megadose blood stem cell transplantation across the HLA barrier: the case for natural killer cells as graft-facilitating cells. Transplantation 1999; 68: 87-88. (Pubitemid 29352836)
87. Asai O, Longo DL, Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrowtransplantation. J Clin Invest 1998; 101:1835-1842. (Pubitemid 28226101)
88. Beelen DW, Ottinger HD, Ferencik S, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005; 105:2594-2600. (Pubitemid 40387064)
89. Fearnley DB, Whyte LF, Carnoutsos SA, et al. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood 1999; 93:728-736. (Pubitemid 29035756)
90. Klangsinsirikul P, Carter GI, Byrne JL, et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99:2586-2591. (Pubitemid 34525449)
91. Damiani D, Stocchi R, Masolini P, et al. CD34+-selected versus unmanipulated autologous stem cell transplantation in multiple myeloma: impact on dendritic and immune recovery and on complications due to infection. Ann Oncol 2003; 14:475-480. (Pubitemid 36367428)
92. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-3057.
93. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28:955-959.
94. Foley B, Cooley S, Verneris MR, et al. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood 2011; 118:2784-2792.
95. Storek J, Ferrara S, Ku N, et al. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993; 12:387-398. (Pubitemid 23295523)
96. Storek J, Lalovic BB, Rupert K, et al. Kinetics of B, CD4 T, and CD8 T cells infused into humans: estimates of intravascular:extravascular ratios and total body counts. Clin Immunol 2002; 102:249-257. (Pubitemid 34259258)
97. Storek J, Witherspoon RP, Webb D, Storb R. Lack of B cell precursors in marrow transplant recipients with chronic GVHD. Am J Hematol 1996; 52:82-89. (Pubitemid 26175047)
98. Storek J, Wells D, Dawson MA, et al. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 2001; 98:489-491.
99. Storek J, Witherspoon RP, Storb R. Reconstitution of membrane IgD-(mIgD-) B cells after marrow transplantation lags behind the reconstitution of mIgD+B cells (letter). Blood 1997; 89:350-351. (Pubitemid 26428216)
100. Small TN, Keever CA, Weiner-Fedus S, et al. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood 1990; 76:1647-1656. (Pubitemid 20364032)
101. Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988; 45:530-534. (Pubitemid 18086554)
102. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to longlived plasma cells. Immunity 1998; 8:363-372. (Pubitemid 28188896)
103. Miller JJ, Cole LJ. The radiation resistance of long-lived lymphocytes and plasma cells in mouse and rat lymph nodes. J Immunol 1967; 98:982-990.
104. Blin N, Traineau R, Houssin S, et al. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant 2010; 16:1315-1323.
105. Fumoux F, Guigou V, Blaise D, et al. Reconstitution of human immunoglobulin VH repertoire after bone marrow transplantation mimics B cell ontogeny. Blood 1993; 81:3153-3157. (Pubitemid 23162137)
106. Minegishi Y, Ishii N, Tsuchida M, et al. T cell reconstitution by haploidentical BMT does not restore the diversification of the Ig heavy chain gene in patients with X-linked SCID. Bone Marrow Transplant 1995; 16:801-806. (Pubitemid 26008440)
107. Glas AM, van Montfort EH, Storek J, et al. B-cell-autonomous somatic mutation deficit following bone marrow transplant. Blood 2000; 96: 1064-1069. (Pubitemid 30616874)
108. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009; 114:4919-4927.
109. Sarantopoulos S, Stevenson KE, Kim HT, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 2011; 117:2275-2283.
110. Kaloyannidis P, Batsis I, Yannaki E, et al. Allografted recipients immunized against hepatitis B virus are at high risk of gradual surface antibody (HbsAb) disappearance post transplant, regardless of adoptive immunity transfer. Biol Blood Marrow Transplant 2007; 13:1049-1056. (Pubitemid 47215561)
111. Engelhard D, Weinberg M, Or R, et al. Immunoglobulins A, G, and M to cytomegalovirus during recurrent infection in recipients of allogeneic bone marrow tranplantation. J Infect Dis 1991; 163:628-630.
112. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994; 57: 677-684. (Pubitemid 24106765)
113. Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps and rubella vaccine. J Infect Dis 1989; 159:610-615. (Pubitemid 19105613)
114. Parkkali T, Olander RM, Ruutu T, et al. A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT. Bone Marrow Transplant 1997; 19:933-938. (Pubitemid 27217662)
115. Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17:434-438.
116. Seidel A, Smith D, Yung E, et al. CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults. Biol Blood Marrow Transplant 2011; 17:524-533.
117. Gueller S, Allwinn R, Mousset S, et al. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:1546-1550.
118. Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 2011; 17:1708-1713.
119. Kier P, Penner E, Bakos S, et al. Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies. Bone Marrow Transplant 1990; 6:93-96. (Pubitemid 20270755)
120. Sanmarco M, Vialettes B, Maraninchi D, Bernard D. Autoantibody formation after bone marrow transplantation: a comparison between autologous and allogeneic grafts. Autoimmunity 1991; 11:7-12.
121. Soderberg C, Larsson S, Rozell BL, et al. Cytomegalovirus-induced CD13-specific autoimmunity: a possible cause of chronic GVHD. Transplantation 1996; 61:600-609. (Pubitemid 26073606)
122. Hebart H, Einsele H, Klein R, et al. CMV infection after allogeneic bone marrow transplantation is associated with the occurence of various autoantibodies and monoclonal gammopathies. Br J Haematol 1996; 95:138-144. (Pubitemid 26340243)
123. Smith CIE, Aarli JA, Biberfeld P, et al. Myasthenia gravis after bone marrow transplantation. Evidence for donor origin. N Engl J Med 1983; 309:1565-1568. (Pubitemid 14212841)
124. Wyatt DT, Lum LG, Casper J, et al. Autoimmune thyroiditis after BMT. Bone Marrow Transplant 1990; 5:357-361.
125. Storek J, Vliagoftis H, Grizel A, et al. Allergy transfer with hematopoietic cell transplantation from an unrelated donor. Bone Marrow Transplant 2011; 46:605-606.
126. Khan F, Hallstrand TS, Geddes MN, et al. Is allergic disease curable or transferable with allogeneic hematopoietic cell transplantation? Blood 2009; 113:279-290.
127. Sullivan KM, Storek J, Kopecky KJ, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic GVHD following marrow transplantation: Clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996; 2:44-53. (Pubitemid 126488195)
128. Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 1995; 16:413-425.
129. Storek J, Joseph A, Dawson MA, et al. Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. Transplantation 2002; 73:1154-1158. (Pubitemid 34415453)
130. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 2001; 97:1458-1466. (Pubitemid 32183773)
131. Storek J, Joseph A, Espino G, et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood 2001; 98:3505-3512.
132. Le RQ, Melenhorst JJ, Battiwalla M, et al. Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation. Blood 2011; 117:5250-5256.
133. Chung B, Barbara-Burnham L, Barsky L, Weinberg K. Radiosensitivity of thymic interleukin-7 production and thymopoiesis after bone marrow transplantation. Blood 2001; 98:1601-1606.
134. Castermans E, Hannon M, Dutrieux J, et al. Thymic recovery after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning is limited to patients younger than 60 years of age. Haematologica 2011; 96:298-306.
135. Sauter C, Abboud M, Jia X, et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant 2011; 17:1460-1471.
136. Marshall NA, Howe JG, Formica R, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000; 96:2814-2821.
137. Ugarte-Torres A, Hoegh-Petersen M, Liu Y, et al. Donor serostatus impacts cytomegalovirus-specific immunity, cytomegaloviral disease incidence and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011; 17:574-585.
138. Hoegh-Petersen M, Roa L, Liu Y, et al. Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors. Cytotherapy 2012; 14:194-204.
139. Kalina T, Lu H, Zhao Z, et al. De novo generation of CD4 T cells against viruses present in the host during immune reconstitution. Blood 2005; 105:2410-2414. (Pubitemid 40387039)
140. Rossi SW, Jeker LT, Ueno T, et al. Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood 2007; 109:3803-3811. (Pubitemid 46641731)
141. Seggewiss R, Lore K, Guenaga FJ, et al. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood 2007; 110:441-449. (Pubitemid 47026867)
142. Chu YW, Schmitz S, Choudhury B, et al. Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood 2008; 112:2836-2846.
143. Lai L, Cui C, Jin J, et al. Mouse embryonic stem cell-derived thymic epithelial cell progenitors enhance T-cell reconstitution after allogeneic bone marrow transplantation. Blood 2011; 118:3410-3418.
144. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113:214-223.
145. Roord ST, de Jager W, Boon L, et al. Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. Blood 2008; 111:5233-5241.
146. Zhang L, Bertucci AM, Ramsey-Goldman R, et al. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol 2009; 183:6346-6358.
147. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9:1144-1150. (Pubitemid 37173698)
148. Cai SF, Cao X, Hassan A, et al. Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. Blood 2010; 115:1669-1677.
149. Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27:635-646. (Pubitemid 47628832)
150. Pastore D, Delia M, Mestice A, et al. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:550-557.
151. Magenau JM, Qin X, Tawara I, et al. Frequency of CD4(+)CD25(hi) FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010; 16:907-914.
152. Mielke S, Rezvani K, Savani BN, et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease. Blood 2007; 110:1689-1697. (Pubitemid 47443988)
153. Miura Y, Thoburn CJ, Bright EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004; 104:2187-2193. (Pubitemid 39297878)
154. Pabst C, Schirutschke H, Ehninger G, et al. The graft content of donor T cells expressing gdTCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin Cancer Res 2007; 13:2916-2922. (Pubitemid 46849566)
155. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108:1291-1297. (Pubitemid 44232027)
156. Wolf D, Wolf AM, Fong D, et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2007; 83:1107-1113. (Pubitemid 46659123)
157. Zhai Z, Sun Z, Li Q, et al. Correlation of the CD4+CD25high T-regulatory cells in recipients and their corresponding donors to acute GVHD. Transplant Int 2007; 20:440-446. (Pubitemid 46535987)
158. Kawano Y, Kim HT, Matsuoka K, et al. Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood 2011; 118:5021-5030.
159. Wu KN, Emmons RV, Lisanti MP, et al. Foxp3-expressing T regulatory cells and mast cells in acute graft-versus-host disease of the skin. Cell Cycle 2009; 8:3593-3597.
160. Meignin V, Peffault de Latour R, Zuber J, et al. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp Hematol 2005; 33:894-900. (Pubitemid 40982655)
161. Sanchez J, Casaño J, Alvarez MA, et al. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2004; 126:697-703. (Pubitemid 39221306)
162. Clark FJ, Gregg R, Piper K, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004; 103:2410-2416. (Pubitemid 38326268)
163. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99:3916-3922. (Pubitemid 35332029)
164. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009; 114:4283-4292.
165. Berger C, Turtle CJ, Jensen MC, Riddell SR. Adoptive transfer of virusspecific and tumor-specific T cell immunity. Curr Opin Immunol 2009; 21:224-232.
166. Sili U, Leen AM, Vera JF, et al. Production of good manufacturing practicegrade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections postallogeneic hematopoietic stem cell transplant. Cytotherapy 2012; 14:7-11.
167. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115:925-935.
168. Bonini C, Brenner MK, Heslop HE, Morgan RA. Genetic modification of T Cells. Biol Blood Marrow Transplant 2011; 17 (Suppl 1):S15-S20.
169. Barker JN, Doubrovina E, Sauter C, et al. Successful treatment of EBVassociated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010; 116: 5045-5049.
170. Qasim W, Derniame S, Gilmour K, et al. Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. Br J Haematol 2011; 154:150-153.
171. Kohrt HE, Muller A, Baker J, et al. Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood 2011; 118:5319-5329.
172. Li N, Matte-Martone C, Zheng H, et al. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood 2011; 118:5965-5976.